Delving into the Latest Updates on Anti-CD37-ATAC(Heidelberg Pharma) with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

anti-CD37-ATAC

Target

CD37

Action

antagonists

Mechanism

CD37 antagonists(Leukocyte antigen CD37 antagonists)

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Hematologic NeoplasmsSolid tumor

Inactive Indication-

Originator Organization

Heidelberg Pharma AG

Active Organization

Heidelberg Pharma AG

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Richter syndrome (RS) is the histol. transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, typically diffuse large B-cell lymphoma (DLBCL), with most cases clonally related to the preceding CLL.The increased interest and efficacy of anti-CD37 -based therapies prompted the development of 3 different anti-CD37-ATACs (amanitin-based ADCs).All 3 anti-CD37 ATACs showed full-blown cytotoxicity on target- pos. Raji cells (Burkitt lymphoma cell line) with half-maximal effective concentration in the low nanomolar and picomolar range (anti-CD37-Ama 1: 2.04 3 10 2 9 M; anti-CD37-Ama 2: 7.5 3 10 2 10 M;anti-CD37-Ama3:3.9 3 10 2 9 M; supplemental Figure 1B).Target specificity was demonstrated by absence of cytotoxicity up to a concentration of 10 2 6 MinaCD37 2 cell line (HEK293 wt ; supplemental Figure 1C).Taken together, the data indicate that CD37 may represent a good candidate for targeting RS cells with highly selective amanitin-based ADCs.

100 Deals associated with Anti-CD37-ATAC(Heidelberg Pharma)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematologic Neoplasms	Preclinical	Denmark	Heidelberg Pharma AG	-
Solid tumor	Preclinical	Denmark	Heidelberg Pharma AG	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data